SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex1-1.htm

Chunk 13 of 21
Word Count: 1421
Character Count: 9003

Document Content:

tombstones. The Underwriters shall be entitled to reimbursement by the Company for all reasonable and documented expenses under Section 3.9.1 – (n), which reimbursement shall not exceed $150,000. In addition, the Company shall be responsible for all fees, expenses and disbursements relating to background checks of the Company’s officers and directors in an amount not to exceed $7,500 in the aggregate. It is acknowledged that the Company has heretofore paid a retainer to the Representative of an aggregate of $[60,000] (the “Retainer”), which shall be applied against the accountable expenses under this Section 3.9.1. The Representative may deduct from the net proceeds of the Offering payable to the Company on the Closing Date and on any Option Closing Date, the expenses set forth herein to be paid by the Company to the Underwriters. Any portion of the Retainer in excess of expenses actually incurred shall be returned to the Company.

Non-accountable Expenses. The Company further agrees that, in addition to the expenses payable pursuant to Section 3.9.1, on the
Closing Date and on any Option Closing Date it shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated
herein, a non-accountable expense allowance equal to one percent (1%) of the gross proceeds received by the Company from the sale of
the Firm Shares and the Option Shares, provided, however, that in the event that the Offering is terminated, the Company agrees to reimburse
the Underwriters pursuant to Section 8.3 hereof.

Application of Net Proceeds. The Company shall apply the net proceeds from the Offering received by it in a manner consistent
with the application thereof described under the caption “Use of Proceeds” in the Registration Statement, the Pricing Disclosure
Package and the Prospectus.

Delivery of Earnings Statement to Security Holders. The Company shall make generally available to its security holders as soon
as practicable, but not later than the first day of the fifteenth (15th) full calendar month following the date of this Agreement, an
earnings statement (which need not be certified by an independent registered public accounting firm unless required by the Securities
Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act)
covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement; provided that such earnings
statement shall be deemed to be made available to the extent it is included in a filing with the Commission on EDGAR.

Stabilization. Neither the Company nor any of its Subsidiaries nor, to its knowledge, any of their respective employees, directors
or stockholders (without the consent of the Representative) has taken or shall take, directly or indirectly, any action designed to or
that has constituted or that might reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise,
stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Public Shares, the
Representative’s Warrants or the Representative Warrant Shares.

Internal Controls. Except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions
are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary in
order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to
assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

Accountants. As of the date of this Agreement, the Company has retained an independent registered public accounting firm reasonably
acceptable to the Representative, and the Company shall continue to retain a nationally recognized independent registered public accounting
firm for a period of at least two (2) years after the date of this Agreement. The Representative acknowledges that the Auditor is acceptable
to the Representative.

FINRA. For a period of 60 days from the later of the Closing Date and any Option Closing Date, except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, the Company shall advise the Representative (who shall make an appropriate
filing with FINRA) if it is or becomes aware that (i) any officer or director of the Company, (ii) any beneficial owner of 10% or more
of any class of the Company’s securities or (iii) any beneficial owner of the Company’s unregistered equity securities which
were acquired during the 180 days immediately preceding the filing of the Registration Statement is or becomes an affiliate or associated
person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).

No Fiduciary Duties. The Company acknowledges and agrees that the Underwriters’ responsibility to the Company is solely
contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary
capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other
transactions contemplated by this Agreement, except as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus.

Company Lock-Up Agreements. The Company, on behalf of itself and any successor entity, agrees that, without the prior written
consent of the Representative, it will not, nor will it publicly disclose an intention to, for a period commencing on the date hereof
and ending 180 days after the Closing Date (the “Lock-Up Period”), (i) offer, issue, pledge, sell (including, without
limitation, any short sale), contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, lend, establish an open “put equivalent position” within the meaning of Rule 16a-1(h)
under the Exchange Act or otherwise transfer or dispose of, or any shares of capital stock of the Company or any securities convertible
into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or caused to be filed any registration statement
with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable
or exchangeable for shares of capital stock of the Company, other than a registration statement on Form S-8; (iii) complete any offering
of debt securities of the Company, other than entering into a line of credit or similar financing agreements; or (iv) enter into any
swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock
of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of shares
of capital stock of the Company or such other securities, in cash or otherwise. The restrictions contained in this Section 3.17 shall
not apply to (a) the Public Shares, Representative’s Warrants and Representative Warrant Shares to be issued pursuant to the terms
hereunder; (b) the issuance by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion
of a security outstanding on the date hereof, or other issuances of additional shares in accordance with the terms of securities, in
each case, as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, provided that such options,
warrants, and securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities or to extend the term of such securities; (c) the issuance
by the Company of stock options or other stock-based awards or the issuance by the Company of shares of capital stock of the Company
under any equity compensation or incentive plan of the Company described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus; and (d) any warrants issued by the Company pursuant to Section 7.4 hereunder as a Future Financing Fee (or any securities
underlying any such warrants); provided that in the case of (b) and (c) above, each recipient of such shares of Common Stock shall be
contractually prohibited from selling, offering, disposing of or otherwise transferring any such shares during the remainder of the Lock-Up
Period.